Protocol Ledger

NCT06615479 · Phase III · RECRUITING

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Interventional Phase III clinical trial protocol NCT06615479 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-12 Enrollment: 440 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06615479
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)440 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06615479
Protocol FieldVerified Registry Value
NCT IdentifierNCT06615479
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment440 participants (ESTIMATED)
Registered Start Date2025-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI